- •Acute outcomes after DBS are favorable.
- •Only 4.9% of individuals with PD had a 30-day non-elective readmission after DBS.
- •Comorbid disease burden was an important risk factor for readmission.
- •The readmission rate for DBS is much lower than that of many common procedures.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.Neurology. 2007; 68: 384-386https://doi.org/10.1212/01.wnl.0000247740.47667.03
- Costs of Parkinson's disease in a privately insured population.PharmacoEconomics. 2013; 31: 799-806https://doi.org/10.1007/s40273-013-0075-0
- Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.Park. Relat. Disord. 2012; 18: 321-326https://doi.org/10.1016/j.parkreldis.2011.11.015
- The current and projected economic burden of Parkinson's disease in the United States.Mov. Disord. Off. J. Mov. Disord. Soc. 2013; 28: 311-318https://doi.org/10.1002/mds.25292
- A randomized trial of deep-brain stimulation for Parkinson's disease.N. Engl. J. Med. 2006; 355: 896-908https://doi.org/10.1056/NEJMoa060281
- Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson's disease.Brain Stimulat. 2016; 9: 78-85https://doi.org/10.1016/j.brs.2015.08.005
- Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease.Ann. Neurol. 2015; 77: 710-719https://doi.org/10.1002/ana.24374
- Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation.Neurology. 2014; 83: 1627-1633https://doi.org/10.1212/WNL.0000000000000943
- Quality of life in advanced Parkinson's disease after bilateral subthalamic stimulation: 2 years follow-up study.Clin. Neurol. Neurosurg. 2014; 124: 161-165https://doi.org/10.1016/j.clineuro.2014.06.019
- Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.Neurology. 2012; 79: 55-65https://doi.org/10.1212/WNL.0b013e31825dcdc1
- Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial.Neurology. 2004; 62: 201-207
- Neurostimulation for Parkinson's disease with early motor complications.N. Engl. J. Med. 2013; 368: 610-622https://doi.org/10.1056/NEJMoa1205158
- Disparities in deep brain stimulation surgery among insured elders with Parkinson disease.Neurology. 2014; 82: 163-171https://doi.org/10.1212/WNL.0000000000000017
- Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.Arch. Neurol. 2005; 62: 601-605https://doi.org/10.1001/archneur.62.4.601
- Sex-related prognostic predictors for Parkinson disease undergoing subthalamic stimulation.World Neurosurg. 2015; 84: 906-912https://doi.org/10.1016/j.wneu.2015.05.023
- Gender differences in quality of life following subthalamic stimulation for Parkinson's disease.Acta Neurol. Scand. 2013; 128: 281-285https://doi.org/10.1111/ane.12127
- Estimating the proportion of essential tremor and Parkinson's disease patients undergoing deep brain stimulation surgery: five-year data from columbia university medical center (2009-2014).Mov. Disord. Clin. Pract. 2015; 2: 384-387https://doi.org/10.1002/mdc3.12185
- Readmissions Reduction Program (HRRP).(07/31/2019)U.S. Centers for Medicare & Medicaid Serviceshttps://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html
- Short-term adverse outcomes after deep brain stimulation treatment in patients with Parkinson disease.World Neurosurg. 2017; 98: 365-374https://doi.org/10.1016/j.wneu.2016.10.138
- Thirty-day readmission rates following deep brain stimulation surgery.Neurosurgery. 2017; 81: 259-267https://doi.org/10.1093/neuros/nyx019
- Complication rates, lengths of stay, and readmission rates in “awake” and “asleep” deep brain simulation.J. Neurosurg. 2017; 127: 360-369https://doi.org/10.3171/2016.6.JNS152946
- Regional trends and the impact of various patient and hospital factors on outcomes and costs of hospitalization between academic and nonacademic centers after deep brain stimulation surgery for Parkinson's disease: a United States Nationwide Inpatient Sample analysis from 2006 to 2010.Neurosurg. Focus. 2013; 35: E2https://doi.org/10.3171/2013.8.FOCUS13295
- Rates, causes, risk factors, and outcomes of readmission following deep brain stimulation for movement disorders: analysis of the U.S. Nationwide Readmissions Database.Clin. Neurol. Neurosurg. 2018; 171: 129-134https://doi.org/10.1016/j.clineuro.2018.06.013
- Healthcare Cost and Utilization Project (HCUP).2013
- Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use.JAMA Neurol. 2014; 71: 291-299https://doi.org/10.1001/jamaneurol.2013.5798
- Comorbidity measures for use with administrative data.Med. Care. 1998; 36: 8-27
- Hospitalization and rehospitalization in Parkinson disease patients: data from the national Parkinson foundation centers of excellence.PLoS One. 2017; 12 (e0180425)https://doi.org/10.1371/journal.pone.0180425
- Early DEtection of wEaring off in Parkinson disease: the DEEP study.Park. Relat. Disord. 2014; 20: 204-211https://doi.org/10.1016/j.parkreldis.2013.10.027
- RAD-PD: Registry for the advancement of DBS in Parkinson's disease.Mov. Disord. 2017; 32: e14